Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2021 | Future treatment of relapsed iNHL

Matthew Matasar • 12 Apr 2021
AACR 2021
Lymphoma Non-Hodgkin Lymphoma Antibodies Copanlisib Rituximab

Matthew Matasar, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the future treatment of indolent non-Hodgkin lymphoma (iNHL), highlighting the use of copanlisib and rituximab in combination. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

Disclosures

Matthew Matasar, MD, has received support and honoraria from Bayer and Roche.

More from Matthew Matasar

1:37
CHRONOS-3: copanlisib plus rituximab for relapsed iNHL
Matthew Matasar • 12 Apr 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals